These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 949876)

  • 1. Accessibility to antibodies of acetylcholine receptors in the neuromuscular junction.
    Zurn AD; Fulpius BW
    Clin Exp Immunol; 1976 Apr; 24(1):9-17. PubMed ID: 949876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies to motor endplates demonstrated with the immunofluorescence technique.
    Sondag-Tschroots IR; Schulz-Raateland RC; van Walbeek HK; Feltkamp TE
    Clin Exp Immunol; 1979 Aug; 37(2):323-7. PubMed ID: 387311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of two different subpopulations of anti-acetylcholine receptor antibodies in a rabbit with experimental auto-immune myasthenia gravis.
    Zurn AD; Fulpius BW
    Eur J Immunol; 1977 Aug; 7(8):529-32. PubMed ID: 902680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A modified assay for antibody against the nicotinic acetylcholine receptor in myasthenia gravis.
    Dwyer DS; Bradley RJ; Oh SJ; Kemp GE
    Clin Exp Immunol; 1979 Sep; 37(3):448-51. PubMed ID: 509779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of myasthenic immunoglobulins against the lethal toxicity of alpha bungarotoxin.
    Vernet-der Garabedian B; Bach JF; Morel E
    Clin Exp Immunol; 1987 Apr; 68(1):130-7. PubMed ID: 3652512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation.
    Drachman DB; Angus CW; Adams RN; Michelson JD; Hoffman GJ
    N Engl J Med; 1978 May; 298(20):1116-22. PubMed ID: 643030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of myasthenic immunoglobulin G on neuromuscular transmission in mouse diaphragm.
    Chiu HC; Chen ML; Tsai MC
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1987 Aug; 20(3):217-23. PubMed ID: 2827968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Heterogeneity of antibodies blocking the binding of bungarotoxin to the acetylcholine receptor in myasthenia].
    Vernet-der-Garabédian B; Morel E; Bach JF
    C R Acad Sci III; 1984; 298(16):449-56. PubMed ID: 6428718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of myasthenic immunoglobulin on acetylcholine receptors of intact mammalian neuromuscular junctions.
    Stanley EF; Drachman DB
    Science; 1978 Jun; 200(4347):1285-7. PubMed ID: 663610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of alpha-bungarotoxin binding to acetylcholine receptors by antisera from animals with experimental autoimmune myasthenia gravis.
    Claudio T; Raftery MA
    J Supramol Struct; 1980; 14(3):267-79. PubMed ID: 6971372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effector mechanisms in myasthenia gravis: end-plate function after passive transfer of IgG, Fab, and F(ab')2 hybrid molecules.
    Sterz R; Hohlfeld R; Rajki K; Kaul M; Heininger K; Peper K; Toyka KV
    Muscle Nerve; 1986 May; 9(4):306-12. PubMed ID: 2423869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. alpha-Bungarotoxin displacing antibody in myasthenia gravis.
    Barkas T; Simpson JA
    J Clin Lab Immunol; 1982 Nov; 9(2):113-7. PubMed ID: 7154056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A myasthenia gravis plasma immunoglobulin reduces miniature endplate potentials at human endplates in vitro.
    Burges J; Wray DW; Pizzighella S; Hall Z; Vincent A
    Muscle Nerve; 1990 May; 13(5):407-13. PubMed ID: 2345558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity.
    Mossman S; Vincent A; Newsom-Davis J
    Lancet; 1986 Jan; 1(8473):116-9. PubMed ID: 2417076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Myasthenia gravis. New results on etiology, diagnosis and therapy].
    Jerusalem F
    Schweiz Med Wochenschr; 1977 Jan; 107(3):65-8. PubMed ID: 402021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. alpha-Bungarotoxin sensitization in experimental autoimmune myasthenia gravis.
    Kennel PF; Poindron P; Warter JM; Fonteneau P
    Muscle Nerve; 1993 May; 16(5):461-5. PubMed ID: 8390605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myasthenia gravis: acetylcholine receptor antibodies and beyond.
    Burde RM
    J Clin Neuroophthalmol; 1981 Mar; 1(1):63-6. PubMed ID: 6213647
    [No Abstract]   [Full Text] [Related]  

  • 19. Passive transfer of seronegative myasthenia gravis to mice.
    Burges J; Vincent A; Molenaar PC; Newsom-Davis J; Peers C; Wray D
    Muscle Nerve; 1994 Dec; 17(12):1393-400. PubMed ID: 7969240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. II. Receptor synthesis.
    Wilson S; Vincent A; Newsom-Davis J
    J Neurol Neurosurg Psychiatry; 1983 May; 46(5):383-7. PubMed ID: 6101172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.